Back to results

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY)

Primary Purpose

Atherosclerosis

Status

Completed

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

Darapladib

Placebo

Sponsored by

GlaxoSmithKline

About this trial

This is an interventional treatment trial for Atherosclerosis focused on measuring heart disease, Lp-PLA2 inhibitor, cardiovascular disease, coronary heart disease, CV risk, Atherosclerosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Men or women at least 18 years old. Women must be post-menopausal or using a highly effective method for avoidance of pregnancy.
Current treatment with statin therapy unless the study doctor determines statins are not appropriate for the subject.
Chronic coronary heart disease
At least one of the following:
At least 60 years old
Diabetes requiring treatment with medication
Low HDL cholesterol ("good cholesterol")
Currently smoke cigarettes or stopped smoking within the past 3 months
Diagnosed mild or moderate reduction in kidney function
Cerebrovascular disease (carotid artery disease or ischemic stroke more than 3 months prior to study entry) OR peripheral arterial disease.

Exclusion Criteria:

Planned coronary revascularization (such as stent placement or heart bypass) or any other major surgical procedure.
Liver disease
Severe reduction in kidney function OR removal of a kidney OR kidney transplant
Severe heart failure
Blood pressure higher than normal despite lifestyle changes and treatment with medications
Any life-threatening disease expected to result in death within the next 2 years (other than heart disease)
Severe asthma that is poorly controlled with medication
Pregnant (Note: A pregnancy test will be performed on all non-sterile women prior to study entry)
Previous severe allergic response to food, drink, insect stings, etc.
Drug or alcohol abuse within the past 6 months OR mental/psychological impairment that may prevent the subject from complying with study procedures or understanding the goal and potential risks of participating in the study.
Certain medications that may interfere with the study medication (these will be identified by the study doctor)
Participation in a study of an investigational medication within the past 30 days
Current participation in a study of an investigational device

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Darapladib

Placebo

Arm Description

Single daily oral tablet

Single daily oral tablet

Outcomes

Primary Outcome Measures

Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal Myocardial Infarction [MI] or Non-fatal Stroke) During the Time Period for Follow-up of CV Events

CV death=death due to a CV cause, which included but was not limited to deaths resulting from stroke, arrhythmia, sudden death (witnessed/unwitnessed), MI, heart failure, pulmonary embolism, peripheral arterial disease, or complications of a CV procedure. Deaths not clearly attributable to non-CV causes are considered to be CV deaths. Acute MI=evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Stroke=presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting >24 hours or results in death (in <24 hours).

Secondary Outcome Measures

Number of Participants With First Occurrence of Any Event in the Composite of Major Coronary Events (Coronary Heart Disease [CHD] Death, Non-fatal MI, or Urgent Coronary Revascularization [CR] for MI) During the Time Period for Follow-up (FU) of CV Events

CHD death=occurrence of a fatal MI, death caused by documented cardiac arrest, death resulting from heart failure in a participant with known CHD, death from other forms of acute/chronic CHD, unwitnessed death of unknown origin, or sudden death. Acute MI=evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g.,silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Urgent CR for MI=ischemic discomfort at rest that prompted CR (percutaneous coronary intervention [PCI: any attempt at CR even if not successful] or coronary artery bypass graft) during the same hospitalization or resulted in hospital transfer for the purpose of CR.

Number of Participants With First Occurrence of Any Event in the Composite of Total Coronary Events (CHD Death, Non-fatal MI, Hospitalization for Unstable Angina, or Any Coronary Revascularization Procedure) During Time Period for FU of CV Events

CHD death, acute MI, and prior MI are defined in the previous secondary endpoint (major coronary events). Hospitalization for unstable angina=one of the following, but not fulfilling the criteria for MI: ischemic discomfort at rest associated with electrocardiogram (ECG) changes leading to hospitalization; ischemic discomfort at rest regardless of ECG changes leading to hospitalization and revascularization during the same admission; ischemic discomfort at rest in hospital associated with ECG changes; ischemic discomfort at rest in hospital without ECG changes resulting in revascularization during the same admission. NOTE: The event was not considered to be unstable angina if, after invasive/non-invasive testing or other diagnostic testing, the discomfort is found not to be caused by myocardial ischemia.

Number of Participants With CV Death During the Time Period for Follow-up of CV Events

CV death is defined as a death due to a CV cause, which included but was not limited to deaths resulting from stroke, arrhythmia, sudden death (witnessed/unwitnessed), MI, heart failure, pulmonary embolism, peripheral arterial disease, or complications of a CV procedure. Deaths not clearly attributable to non-CV causes are considered to be CV deaths.

Number of Participants With First Occurrence of MI (Fatal/Non-fatal) During the Time Period for Follow-up of CV Events

Acute MI is defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI.

Number of Participants With First Occurrence of Stroke (Fatal/Non-fatal) During the Time Period for Follow-up of CV Events

Stroke is defined as the presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting >24 hours or results in death (in <24 hours).

Number of Participants With First Occurrence of Any Component of the Composite of All-cause Mortality, Non-fatal MI, or Non-fatal Stroke During the Time Period for Follow-up of CV Events

Acute MI is defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Stroke=presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting >24 hours or results in death (in <24 hours).

Number of Participants With All-cause Mortality During the Time Period for Vital Status

The number of participants with all-cause mortality was assessed.

Full Information

NCT ID

First Posted

November 26, 2008

Last Updated

July 12, 2017

Sponsor

GlaxoSmithKline

1. Study Identification

Unique Protocol Identification Number

NCT00799903

Brief Title

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Acronym

STABILITY

Official Title

LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)

Study Type

Interventional

2. Study Status

Record Verification Date

March 2017

Overall Recruitment Status

Completed

Study Start Date

December 1, 2008 (undefined)

Primary Completion Date

October 1, 2013 (Actual)

Study Completion Date

October 17, 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

GlaxoSmithKline

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.

Detailed Description

Subjects who qualify for the study will be randomized 1:1 to either darapladib or placebo administered in addition to standard therapy. Following the baseline visit, subjects will be expected to return for clinic visits at 1 month, 3 months, and every 6 months until the end of the study. Average time in the study for an individual subject is expected to be about 3 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Atherosclerosis

Keywords

heart disease, Lp-PLA2 inhibitor, cardiovascular disease, coronary heart disease, CV risk, Atherosclerosis

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

15828 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Darapladib

Arm Type

Experimental

Arm Description

Single daily oral tablet

Arm Title

Placebo

Arm Type

Placebo Comparator

Arm Description

Single daily oral tablet

Intervention Type

Drug

Intervention Name(s)

Darapladib

Intervention Description

Lp-PLA2 inhibitor administered in addition to standard therapy

Intervention Type

Drug

Intervention Name(s)

Placebo

Intervention Description

Placebo administered in addition to standard therapy

Primary Outcome Measure Information:

Title

Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal Myocardial Infarction [MI] or Non-fatal Stroke) During the Time Period for Follow-up of CV Events

Description

CV death=death due to a CV cause, which included but was not limited to deaths resulting from stroke, arrhythmia, sudden death (witnessed/unwitnessed), MI, heart failure, pulmonary embolism, peripheral arterial disease, or complications of a CV procedure. Deaths not clearly attributable to non-CV causes are considered to be CV deaths. Acute MI=evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Stroke=presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting >24 hours or results in death (in <24 hours).

Time Frame

From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)

Secondary Outcome Measure Information:

Title

Number of Participants With First Occurrence of Any Event in the Composite of Major Coronary Events (Coronary Heart Disease [CHD] Death, Non-fatal MI, or Urgent Coronary Revascularization [CR] for MI) During the Time Period for Follow-up (FU) of CV Events

Description

CHD death=occurrence of a fatal MI, death caused by documented cardiac arrest, death resulting from heart failure in a participant with known CHD, death from other forms of acute/chronic CHD, unwitnessed death of unknown origin, or sudden death. Acute MI=evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g.,silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Urgent CR for MI=ischemic discomfort at rest that prompted CR (percutaneous coronary intervention [PCI: any attempt at CR even if not successful] or coronary artery bypass graft) during the same hospitalization or resulted in hospital transfer for the purpose of CR.

Time Frame

From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)

Title

Number of Participants With First Occurrence of Any Event in the Composite of Total Coronary Events (CHD Death, Non-fatal MI, Hospitalization for Unstable Angina, or Any Coronary Revascularization Procedure) During Time Period for FU of CV Events

Description

CHD death, acute MI, and prior MI are defined in the previous secondary endpoint (major coronary events). Hospitalization for unstable angina=one of the following, but not fulfilling the criteria for MI: ischemic discomfort at rest associated with electrocardiogram (ECG) changes leading to hospitalization; ischemic discomfort at rest regardless of ECG changes leading to hospitalization and revascularization during the same admission; ischemic discomfort at rest in hospital associated with ECG changes; ischemic discomfort at rest in hospital without ECG changes resulting in revascularization during the same admission. NOTE: The event was not considered to be unstable angina if, after invasive/non-invasive testing or other diagnostic testing, the discomfort is found not to be caused by myocardial ischemia.

Time Frame

From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)

Title

Number of Participants With CV Death During the Time Period for Follow-up of CV Events

Description

CV death is defined as a death due to a CV cause, which included but was not limited to deaths resulting from stroke, arrhythmia, sudden death (witnessed/unwitnessed), MI, heart failure, pulmonary embolism, peripheral arterial disease, or complications of a CV procedure. Deaths not clearly attributable to non-CV causes are considered to be CV deaths.

Time Frame

From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)

Title

Number of Participants With First Occurrence of MI (Fatal/Non-fatal) During the Time Period for Follow-up of CV Events

Description

Acute MI is defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI.

Time Frame

From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)

Title

Number of Participants With First Occurrence of Stroke (Fatal/Non-fatal) During the Time Period for Follow-up of CV Events

Description

Stroke is defined as the presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting >24 hours or results in death (in <24 hours).

Time Frame

From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)

Title

Number of Participants With First Occurrence of Any Component of the Composite of All-cause Mortality, Non-fatal MI, or Non-fatal Stroke During the Time Period for Follow-up of CV Events

Description

Acute MI is defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Prior MI diagnosed post-randomization (e.g., silent MI)=the development of new pathological Q waves with/without symptoms OR imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischemic cause (pre-event imaging data required for verification of new abnormality), OR pathological findings of a healed/healing MI. Stroke=presence of a new focal neurologic deficit thought to be of vascular origin, with signs/symptoms lasting >24 hours or results in death (in <24 hours).

Time Frame

From randomization until the End-of-Treatment visit or the last date on which endpoints were able to be assessed (up to 4.25 years/average of 3.51 years)

Title

Number of Participants With All-cause Mortality During the Time Period for Vital Status

Description

The number of participants with all-cause mortality was assessed.

Time Frame

From randomization until death or study completion (up to 4.49 years/average of 3.65 years)

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria: Men or women at least 18 years old. Women must be post-menopausal or using a highly effective method for avoidance of pregnancy. Current treatment with statin therapy unless the study doctor determines statins are not appropriate for the subject. Chronic coronary heart disease At least one of the following: At least 60 years old Diabetes requiring treatment with medication Low HDL cholesterol ("good cholesterol") Currently smoke cigarettes or stopped smoking within the past 3 months Diagnosed mild or moderate reduction in kidney function Cerebrovascular disease (carotid artery disease or ischemic stroke more than 3 months prior to study entry) OR peripheral arterial disease. Exclusion Criteria: Planned coronary revascularization (such as stent placement or heart bypass) or any other major surgical procedure. Liver disease Severe reduction in kidney function OR removal of a kidney OR kidney transplant Severe heart failure Blood pressure higher than normal despite lifestyle changes and treatment with medications Any life-threatening disease expected to result in death within the next 2 years (other than heart disease) Severe asthma that is poorly controlled with medication Pregnant (Note: A pregnancy test will be performed on all non-sterile women prior to study entry) Previous severe allergic response to food, drink, insect stings, etc. Drug or alcohol abuse within the past 6 months OR mental/psychological impairment that may prevent the subject from complying with study procedures or understanding the goal and potential risks of participating in the study. Certain medications that may interfere with the study medication (these will be identified by the study doctor) Participation in a study of an investigational medication within the past 30 days Current participation in a study of an investigational device

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

GSK Clinical Trials

Organizational Affiliation

GlaxoSmithKline

Official's Role

Study Director

Facility Information:

Facility Name

GSK Investigational Site

City

Birmingham

State/Province

Alabama

ZIP/Postal Code

35235

Country

United States

Facility Name

GSK Investigational Site

City

Birmingham

State/Province

Alabama

ZIP/Postal Code

35294-0007

Country

United States

Facility Name

GSK Investigational Site

City

Huntsville

State/Province

Alabama

ZIP/Postal Code

35801

Country

United States

Facility Name

GSK Investigational Site

City

Anchorage

State/Province

Alaska

ZIP/Postal Code

99508

Country

United States

Facility Name

GSK Investigational Site

City

Little Rock

State/Province

Arkansas

ZIP/Postal Code

72204

Country

United States

Facility Name

GSK Investigational Site

City

Concord

State/Province

California

ZIP/Postal Code

94520

Country

United States

Facility Name

GSK Investigational Site

City

Lomita

State/Province

California

ZIP/Postal Code

90717

Country

United States

Facility Name

GSK Investigational Site

City

Los Angeles

State/Province

California

ZIP/Postal Code

90024

Country

United States

Facility Name

GSK Investigational Site

City

Los Angeles

State/Province

California

ZIP/Postal Code

90036

Country

United States

Facility Name

GSK Investigational Site

City

Madera

State/Province

California

ZIP/Postal Code

93637

Country

United States

Facility Name

GSK Investigational Site

City

Oakland

State/Province

California

ZIP/Postal Code

94611

Country

United States

Facility Name

GSK Investigational Site

City

Oakland

State/Province

California

ZIP/Postal Code

94612

Country

United States

Facility Name

GSK Investigational Site

City

Poway

State/Province

California

ZIP/Postal Code

92064

Country

United States

Facility Name

GSK Investigational Site

City

Sacramento

State/Province

California

ZIP/Postal Code

95819

Country

United States

Facility Name

GSK Investigational Site

City

San Diego

State/Province

California

ZIP/Postal Code

92161

Country

United States

Facility Name

GSK Investigational Site

City

San Ramon

State/Province

California

ZIP/Postal Code

94582

Country

United States

Facility Name

GSK Investigational Site

City

Santa Ana

State/Province

California

ZIP/Postal Code

92705

Country

United States

Facility Name

GSK Investigational Site

City

Spring Valley

State/Province

California

ZIP/Postal Code

91978

Country

United States

Facility Name

GSK Investigational Site

City

Thousand Oaks

State/Province

California

ZIP/Postal Code

91360

Country

United States

Facility Name

GSK Investigational Site

City

Colorado Springs

State/Province

Colorado

ZIP/Postal Code

80920

Country

United States

Facility Name

GSK Investigational Site

City

Denver

State/Province

Colorado

ZIP/Postal Code

80218

Country

United States

Facility Name

GSK Investigational Site

City

Golden

State/Province

Colorado

ZIP/Postal Code

80401

Country

United States

Facility Name

GSK Investigational Site

City

Thornton

State/Province

Colorado

ZIP/Postal Code

80229

Country

United States

Facility Name

GSK Investigational Site

City

Bridgeport

State/Province

Connecticut

ZIP/Postal Code

06606

Country

United States

Facility Name

GSK Investigational Site

City

Bridgeport

State/Province

Connecticut

ZIP/Postal Code

06610

Country

United States

Facility Name

GSK Investigational Site

City

Hartford

State/Province

Connecticut

ZIP/Postal Code

06067

Country

United States

Facility Name

GSK Investigational Site

City

Newark

State/Province

Delaware

ZIP/Postal Code

19718

Country

United States

Facility Name

GSK Investigational Site

City

Atlantis

State/Province

Florida

ZIP/Postal Code

33462

Country

United States

Facility Name

GSK Investigational Site

City

Gainesville

State/Province

Florida

ZIP/Postal Code

32610

Country

United States

Facility Name

GSK Investigational Site

City

Hollywood

State/Province

Florida

ZIP/Postal Code

33023

Country

United States

Facility Name

GSK Investigational Site

City

Jacksonville Beach

State/Province

Florida

ZIP/Postal Code

32250

Country

United States

Facility Name

GSK Investigational Site

City

Jacksonville

State/Province

Florida

ZIP/Postal Code

32207

Country

United States

Facility Name

GSK Investigational Site

City

Jacksonville

State/Province

Florida

ZIP/Postal Code

32216

Country

United States

Facility Name

GSK Investigational Site

City

Jacksonville

State/Province

Florida

ZIP/Postal Code

32258

Country

United States

Facility Name

GSK Investigational Site

City

Miami

State/Province

Florida

ZIP/Postal Code

33136

Country

United States

Facility Name

GSK Investigational Site

City

Miami

State/Province

Florida

ZIP/Postal Code

33183

Country

United States

Facility Name

GSK Investigational Site

City

Ocala

State/Province

Florida

ZIP/Postal Code

34471

Country

United States

Facility Name

GSK Investigational Site

City

Ponte Vedra Beach

State/Province

Florida

ZIP/Postal Code

32081

Country

United States

Facility Name

GSK Investigational Site

City

Conyers

State/Province

Georgia

ZIP/Postal Code

30094

Country

United States

Facility Name

GSK Investigational Site

City

Aurora

State/Province

Illinois

ZIP/Postal Code

60504

Country

United States

Facility Name

GSK Investigational Site

City

Chicago

State/Province

Illinois

ZIP/Postal Code

60654

Country

United States

Facility Name

GSK Investigational Site

City

Melrose Park

State/Province

Illinois

ZIP/Postal Code

60160

Country

United States

Facility Name

GSK Investigational Site

City

Avon

State/Province

Indiana

ZIP/Postal Code

46123

Country

United States

Facility Name

GSK Investigational Site

City

Franklin

State/Province

Indiana

ZIP/Postal Code

46131

Country

United States

Facility Name

GSK Investigational Site

City

Greenfield

State/Province

Indiana

ZIP/Postal Code

46140

Country

United States

Facility Name

GSK Investigational Site

City

Indianapolis

State/Province

Indiana

ZIP/Postal Code

46256

Country

United States

Facility Name

GSK Investigational Site

City

Indianapolis

State/Province

Indiana

ZIP/Postal Code

46260

Country

United States

Facility Name

GSK Investigational Site

City

Valparaiso

State/Province

Indiana

ZIP/Postal Code

46383

Country

United States

Facility Name

GSK Investigational Site

City

Iowa City

State/Province

Iowa

ZIP/Postal Code

52242

Country

United States

Facility Name

GSK Investigational Site

City

West Des Moines

State/Province

Iowa

ZIP/Postal Code

50266

Country

United States

Facility Name

GSK Investigational Site

City

Crestview Hills

State/Province

Kentucky

ZIP/Postal Code

41017

Country

United States

Facility Name

GSK Investigational Site

City

Louisville

State/Province

Kentucky

ZIP/Postal Code

40206

Country

United States

Facility Name

GSK Investigational Site

City

Louisville

State/Province

Kentucky

ZIP/Postal Code

40213

Country

United States

Facility Name

GSK Investigational Site

City

Lafayette

State/Province

Louisiana

ZIP/Postal Code

70503

Country

United States

Facility Name

GSK Investigational Site

City

New Iberia

State/Province

Louisiana

ZIP/Postal Code

70563

Country

United States

Facility Name

GSK Investigational Site

City

Slidell

State/Province

Louisiana

ZIP/Postal Code

70458

Country

United States

Facility Name

GSK Investigational Site

City

Auburn

State/Province

Maine

ZIP/Postal Code

04210

Country

United States

Facility Name

GSK Investigational Site

City

Bangor

State/Province

Maine

ZIP/Postal Code

04401

Country

United States

Facility Name

GSK Investigational Site

City

Scarborough

State/Province

Maine

ZIP/Postal Code

04074

Country

United States

Facility Name

GSK Investigational Site

City

Baltimore

State/Province

Maryland

ZIP/Postal Code

21209

Country

United States

Facility Name

GSK Investigational Site

City

Oxon Hill

State/Province

Maryland

ZIP/Postal Code

20745

Country

United States

Facility Name

GSK Investigational Site

City

Prince Frederick

State/Province

Maryland

ZIP/Postal Code

20678

Country

United States

Facility Name

GSK Investigational Site

City

Boston

State/Province

Massachusetts

ZIP/Postal Code

02111

Country

United States

Facility Name

GSK Investigational Site

City

Natick

State/Province

Massachusetts

ZIP/Postal Code

01760

Country

United States

Facility Name

GSK Investigational Site

City

Springfield

State/Province

Massachusetts

ZIP/Postal Code

01103

Country

United States

Facility Name

GSK Investigational Site

City

Cadillac

State/Province

Michigan

ZIP/Postal Code

49601

Country

United States

Facility Name

GSK Investigational Site

City

Detroit

State/Province

Michigan

ZIP/Postal Code

48202

Country

United States

Facility Name

GSK Investigational Site

City

Petoskey

State/Province

Michigan

ZIP/Postal Code

49770

Country

United States

Facility Name

GSK Investigational Site

City

Saint Cloud

State/Province

Minnesota

ZIP/Postal Code

56303

Country

United States

Facility Name

GSK Investigational Site

City

Saint Louis

State/Province

Missouri

ZIP/Postal Code

63110

Country

United States

Facility Name

GSK Investigational Site

City

Grand Island

State/Province

Nebraska

ZIP/Postal Code

68803

Country

United States

Facility Name

GSK Investigational Site

City

Las Vegas

State/Province

Nevada

ZIP/Postal Code

89103

Country

United States

Facility Name

GSK Investigational Site

City

Las Vegas

State/Province

Nevada

ZIP/Postal Code

89130

Country

United States

Facility Name

GSK Investigational Site

City

Browns Mills

State/Province

New Jersey

ZIP/Postal Code

08015

Country

United States

Facility Name

GSK Investigational Site

City

Elizabeth

State/Province

New Jersey

ZIP/Postal Code

07202

Country

United States

Facility Name

GSK Investigational Site

City

West Orange

State/Province

New Jersey

ZIP/Postal Code

07052

Country

United States

Facility Name

GSK Investigational Site

City

Albuquerque

State/Province

New Mexico

ZIP/Postal Code

87102

Country

United States

Facility Name

GSK Investigational Site

City

Buffalo

State/Province

New York

ZIP/Postal Code

14215

Country

United States

Facility Name

GSK Investigational Site

City

New York

State/Province

New York

ZIP/Postal Code

10001

Country

United States

Facility Name

GSK Investigational Site

City

New York

State/Province

New York

ZIP/Postal Code

10016

Country

United States

Facility Name

GSK Investigational Site

City

New York

State/Province

New York

ZIP/Postal Code

10021

Country

United States

Facility Name

GSK Investigational Site

City

Westfield

State/Province

New York

ZIP/Postal Code

14787

Country

United States

Facility Name

GSK Investigational Site

City

Williamsville

State/Province

New York

ZIP/Postal Code

14221

Country

United States

Facility Name

GSK Investigational Site

City

Charlotte

State/Province

North Carolina

ZIP/Postal Code

28204

Country

United States

Facility Name

GSK Investigational Site

City

Durham

State/Province

North Carolina

ZIP/Postal Code

27710

Country

United States

Facility Name

GSK Investigational Site

City

Gastonia

State/Province

North Carolina

ZIP/Postal Code

28054

Country

United States

Facility Name

GSK Investigational Site

City

Matthews

State/Province

North Carolina

ZIP/Postal Code

28105

Country

United States

Facility Name

GSK Investigational Site

City

Salisbury

State/Province

North Carolina

ZIP/Postal Code

28144

Country

United States

Facility Name

GSK Investigational Site

City

Statesville

State/Province

North Carolina

ZIP/Postal Code

28677

Country

United States

Facility Name

GSK Investigational Site

City

Wilmington

State/Province

North Carolina

ZIP/Postal Code

28401

Country

United States

Facility Name

GSK Investigational Site

City

Grand Forks

State/Province

North Dakota

ZIP/Postal Code

58201

Country

United States

Facility Name

GSK Investigational Site

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45227

Country

United States

Facility Name

GSK Investigational Site

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45246

Country

United States

Facility Name

GSK Investigational Site

City

Elyria

State/Province

Ohio

ZIP/Postal Code

44035

Country

United States

Facility Name

GSK Investigational Site

City

Garfield Heights

State/Province

Ohio

ZIP/Postal Code

44125

Country

United States

Facility Name

GSK Investigational Site

City

Kettering

State/Province

Ohio

ZIP/Postal Code

45429

Country

United States

Facility Name

GSK Investigational Site

City

Middleburg Heights

State/Province

Ohio

ZIP/Postal Code

44130

Country

United States

Facility Name

GSK Investigational Site

City

Sandusky

State/Province

Ohio

ZIP/Postal Code

44870

Country

United States

Facility Name

GSK Investigational Site

City

Toledo

State/Province

Ohio

ZIP/Postal Code

43614

Country

United States

Facility Name

GSK Investigational Site

City

Westlake

State/Province

Ohio

ZIP/Postal Code

44145

Country

United States

Facility Name

GSK Investigational Site

City

Oklahoma City

State/Province

Oklahoma

ZIP/Postal Code

73120

Country

United States

Facility Name

GSK Investigational Site

City

Portland

State/Province

Oregon

ZIP/Postal Code

97219

Country

United States

Facility Name

GSK Investigational Site

City

Beaver

State/Province

Pennsylvania

ZIP/Postal Code

15009

Country

United States

Facility Name

GSK Investigational Site

City

Danville

State/Province

Pennsylvania

ZIP/Postal Code

17822-4201

Country

United States

Facility Name

GSK Investigational Site

City

Doylestown

State/Province

Pennsylvania

ZIP/Postal Code

18901

Country

United States

Facility Name

GSK Investigational Site

City

Erie

State/Province

Pennsylvania

ZIP/Postal Code

16502

Country

United States

Facility Name

GSK Investigational Site

City

Jersey Shore

State/Province

Pennsylvania

ZIP/Postal Code

17740

Country

United States

Facility Name

GSK Investigational Site

City

Lewistown

State/Province

Pennsylvania

ZIP/Postal Code

17044

Country

United States

Facility Name

GSK Investigational Site

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19104

Country

United States

Facility Name

GSK Investigational Site

City

Philipsburg

State/Province

Pennsylvania

ZIP/Postal Code

16866

Country

United States

Facility Name

GSK Investigational Site

City

Pittsburgh

State/Province

Pennsylvania

ZIP/Postal Code

15212

Country

United States

Facility Name

GSK Investigational Site

City

Port Matilda

State/Province

Pennsylvania

ZIP/Postal Code

16870

Country

United States

Facility Name

GSK Investigational Site

City

Sayre

State/Province

Pennsylvania

ZIP/Postal Code

18840

Country

United States

Facility Name

GSK Investigational Site

City

Scranton

State/Province

Pennsylvania

ZIP/Postal Code

18503

Country

United States

Facility Name

GSK Investigational Site

City

Scranton

State/Province

Pennsylvania

ZIP/Postal Code

18505

Country

United States

Facility Name

GSK Investigational Site

City

Sellersville

State/Province

Pennsylvania

ZIP/Postal Code

18960

Country

United States

Facility Name

GSK Investigational Site

City

Wilkes-Barre

State/Province

Pennsylvania

ZIP/Postal Code

18702

Country

United States

Facility Name

GSK Investigational Site

City

York

State/Province

Pennsylvania

ZIP/Postal Code

17403

Country

United States

Facility Name

GSK Investigational Site

City

Providence

State/Province

Rhode Island

ZIP/Postal Code

02904

Country

United States

Facility Name

GSK Investigational Site

City

Charleston

State/Province

South Carolina

ZIP/Postal Code

29401

Country

United States

Facility Name

GSK Investigational Site

City

Charleston

State/Province

South Carolina

ZIP/Postal Code

29425-6240

Country

United States

Facility Name

GSK Investigational Site

City

Spartanburg

State/Province

South Carolina

ZIP/Postal Code

29303

Country

United States

Facility Name

GSK Investigational Site

City

Rapid City

State/Province

South Dakota

ZIP/Postal Code

57701

Country

United States

Facility Name

GSK Investigational Site

City

Sioux Falls

State/Province

South Dakota

ZIP/Postal Code

57105

Country

United States

Facility Name

GSK Investigational Site

City

Bristol

State/Province

Tennessee

ZIP/Postal Code

37620

Country

United States

Facility Name

GSK Investigational Site

City

Johnson City

State/Province

Tennessee

ZIP/Postal Code

37601

Country

United States

Facility Name

GSK Investigational Site

City

Amarillo

State/Province

Texas

ZIP/Postal Code

79106

Country

United States

Facility Name

GSK Investigational Site

City

Austin

State/Province

Texas

ZIP/Postal Code

78705

Country

United States

Facility Name

GSK Investigational Site

City

Corpus Christi

State/Province

Texas

ZIP/Postal Code

78404

Country

United States

Facility Name

GSK Investigational Site

City

Dallas

State/Province

Texas

ZIP/Postal Code

75226

Country

United States

Facility Name

GSK Investigational Site

City

Dallas

State/Province

Texas

ZIP/Postal Code

75231

Country

United States

Facility Name

GSK Investigational Site

City

Georgetown

State/Province

Texas

ZIP/Postal Code

78626

Country

United States

Facility Name

GSK Investigational Site

City

Harker Heights

State/Province

Texas

ZIP/Postal Code

76548

Country

United States

Facility Name

GSK Investigational Site

City

Houston

State/Province

Texas

ZIP/Postal Code

77030

Country

United States

Facility Name

GSK Investigational Site

City

Houston

State/Province

Texas

ZIP/Postal Code

77081

Country

United States

Facility Name

GSK Investigational Site

City

Plano

State/Province

Texas

ZIP/Postal Code

75024

Country

United States

Facility Name

GSK Investigational Site

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78217

Country

United States

Facility Name

GSK Investigational Site

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78244

Country

United States

Facility Name

GSK Investigational Site

City

Victoria

State/Province

Texas

ZIP/Postal Code

77901

Country

United States

Facility Name

GSK Investigational Site

City

Draper

State/Province

Utah

ZIP/Postal Code

84020

Country

United States

Facility Name

GSK Investigational Site

City

Burke

State/Province

Virginia

ZIP/Postal Code

22015

Country

United States

Facility Name

GSK Investigational Site

City

Norfolk

State/Province

Virginia

ZIP/Postal Code

23502

Country

United States

Facility Name

GSK Investigational Site

City

Richmond

State/Province

Virginia

ZIP/Postal Code

23294

Country

United States

Facility Name

GSK Investigational Site

City

Winchester

State/Province

Virginia

ZIP/Postal Code

22601

Country

United States

Facility Name

GSK Investigational Site

City

Kirkland

State/Province

Washington

ZIP/Postal Code

98034

Country

United States

Facility Name

GSK Investigational Site

City

Olympia

State/Province

Washington

ZIP/Postal Code

98502

Country

United States

Facility Name

GSK Investigational Site

City

Renton

State/Province

Washington

ZIP/Postal Code

98057

Country

United States

Facility Name

GSK Investigational Site

City

Seattle

State/Province

Washington

ZIP/Postal Code

98104

Country

United States

Facility Name

GSK Investigational Site

City

Spokane

State/Province

Washington

ZIP/Postal Code

99204

Country

United States

Facility Name

GSK Investigational Site

City

Spokane

State/Province

Washington

ZIP/Postal Code

99207

Country

United States

Facility Name

GSK Investigational Site

City

Spokane

State/Province

Washington

ZIP/Postal Code

99208

Country

United States

Facility Name

GSK Investigational Site

City

Tacoma

State/Province

Washington

ZIP/Postal Code

98405

Country

United States

Facility Name

GSK Investigational Site

City

Walla Walla

State/Province

Washington

ZIP/Postal Code

99362

Country

United States

Facility Name

GSK Investigational Site

City

Wenatchee

State/Province

Washington

ZIP/Postal Code

98801

Country

United States

Facility Name

GSK Investigational Site

City

Wausau

State/Province

Wisconsin

ZIP/Postal Code

54401

Country

United States

Facility Name

GSK Investigational Site

City

Adrogue

State/Province

Buenos Aires

ZIP/Postal Code

B1846DSK

Country

Argentina

Facility Name

GSK Investigational Site

City

Bahia Blanca

State/Province

Buenos Aires

ZIP/Postal Code

B8000FTD

Country

Argentina

Facility Name

GSK Investigational Site

City

Caba

State/Province

Buenos Aires

ZIP/Postal Code

C1124AAJ

Country

Argentina

Facility Name

GSK Investigational Site

City

Ciudad Autonoma de Buenos Aires

State/Province

Buenos Aires

ZIP/Postal Code

C1405BCH

Country

Argentina

Facility Name

GSK Investigational Site

City

Ciudad Autónoma de Buenos Aires

State/Province

Buenos Aires

ZIP/Postal Code

C1125ABD

Country

Argentina

Facility Name

GSK Investigational Site

City

Ciudad Autónoma de Buenos Aires

State/Province

Buenos Aires

ZIP/Postal Code

C1437JCP

Country

Argentina

Facility Name

GSK Investigational Site

City

Junin

State/Province

Buenos Aires

Country

Argentina

Facility Name

GSK Investigational Site

City

La Plata

State/Province

Buenos Aires

ZIP/Postal Code

B1900AXI

Country

Argentina

Facility Name

GSK Investigational Site

City

Mar del Plata

State/Province

Buenos Aires

ZIP/Postal Code

B7600FZN

Country

Argentina

Facility Name

GSK Investigational Site

City

Ramos Mejia

State/Province

Buenos Aires

ZIP/Postal Code

B1704ETD

Country

Argentina

Facility Name

GSK Investigational Site

City

Cordoba

State/Province

Córdova

ZIP/Postal Code

X5000EPU

Country

Argentina

Facility Name

GSK Investigational Site

City

Rosario

State/Province

Santa Fe

ZIP/Postal Code

S2000CVD

Country

Argentina

Facility Name

GSK Investigational Site

City

Buenos Aires

ZIP/Postal Code

1425

Country

Argentina

Facility Name

GSK Investigational Site

City

Corrientes

ZIP/Postal Code

W3400AMZ

Country

Argentina

Facility Name

GSK Investigational Site

City

Corrientes

ZIP/Postal Code

W3400CLH

Country

Argentina

Facility Name

GSK Investigational Site

City

Mendoza

ZIP/Postal Code

M5500CCG

Country

Argentina

Facility Name

GSK Investigational Site

City

Santa Fe

ZIP/Postal Code

3000

Country

Argentina

Facility Name

GSK Investigational Site

City

Tucuman

ZIP/Postal Code

T4000ICL

Country

Argentina

Facility Name

GSK Investigational Site

City

Garran

State/Province

Australian Capital Territory

ZIP/Postal Code

2606

Country

Australia

Facility Name

GSK Investigational Site

City

Coffs Harbour

State/Province

New South Wales

ZIP/Postal Code

2450

Country

Australia

Facility Name

GSK Investigational Site

City

Concord

State/Province

New South Wales

ZIP/Postal Code

2139

Country

Australia

Facility Name

GSK Investigational Site

City

Gosford

State/Province

New South Wales

ZIP/Postal Code

2250

Country

Australia

Facility Name

GSK Investigational Site

City

Liverpool

State/Province

New South Wales

ZIP/Postal Code

2170

Country

Australia

Facility Name

GSK Investigational Site

City

Auchenflower

State/Province

Queensland

ZIP/Postal Code

4066

Country

Australia

Facility Name

GSK Investigational Site

City

Kippa Ring

State/Province

Queensland

ZIP/Postal Code

4021

Country

Australia

Facility Name

GSK Investigational Site

City

Sherwood

State/Province

Queensland

ZIP/Postal Code

4075

Country

Australia

Facility Name

GSK Investigational Site

City

Bedford Park

State/Province

South Australia

ZIP/Postal Code

5042

Country

Australia

Facility Name

GSK Investigational Site

City

Ballarat

State/Province

Victoria

Country

Australia

Facility Name

GSK Investigational Site

City

Caulfield South

State/Province

Victoria

ZIP/Postal Code

3162

Country

Australia

Facility Name

GSK Investigational Site

City

Frankston

State/Province

Victoria

ZIP/Postal Code

3199

Country

Australia

Facility Name

GSK Investigational Site

City

Malvern

State/Province

Victoria

ZIP/Postal Code

3144

Country

Australia

Facility Name

GSK Investigational Site

City

Fremantle

State/Province

Western Australia

ZIP/Postal Code

6160

Country

Australia

Facility Name

GSK Investigational Site

City

Joondalup

State/Province

Western Australia

ZIP/Postal Code

6027

Country

Australia

Facility Name

GSK Investigational Site

City

Nedlands

State/Province

Western Australia

ZIP/Postal Code

6009

Country

Australia

Facility Name

GSK Investigational Site

City

Aalst

ZIP/Postal Code

9300

Country

Belgium

Facility Name

GSK Investigational Site

City

Antwerpen

ZIP/Postal Code

2020

Country

Belgium

Facility Name

GSK Investigational Site

City

Bonheiden

ZIP/Postal Code

2820

Country

Belgium

Facility Name

GSK Investigational Site

City

Bruxelles

ZIP/Postal Code

1200

Country

Belgium

Facility Name

GSK Investigational Site

City

Genk

ZIP/Postal Code

3600

Country

Belgium

Facility Name

GSK Investigational Site

City

Hasselt

ZIP/Postal Code

3500

Country

Belgium

Facility Name

GSK Investigational Site

City

La Louvière

ZIP/Postal Code

7100

Country

Belgium

Facility Name

GSK Investigational Site

City

Leuven

ZIP/Postal Code

3000

Country

Belgium

Facility Name

GSK Investigational Site

City

Liège

ZIP/Postal Code

4000

Country

Belgium

Facility Name

GSK Investigational Site

City

Roeselaere

ZIP/Postal Code

8800

Country

Belgium

Facility Name

GSK Investigational Site

City

Yvoir

ZIP/Postal Code

5530

Country

Belgium

Facility Name

GSK Investigational Site

City

Salvador

State/Province

Bahía

ZIP/Postal Code

41810010

Country

Brazil

Facility Name

GSK Investigational Site

City

Goiânia

State/Province

Goiás

ZIP/Postal Code

74605-050

Country

Brazil

Facility Name

GSK Investigational Site

City

Belo Horizonte

State/Province

Minas Gerais

ZIP/Postal Code

30150-221.

Country

Brazil

Facility Name

GSK Investigational Site

City

Belo Horizonte

State/Province

Minas Gerais

ZIP/Postal Code

30380090

Country

Brazil

Facility Name

GSK Investigational Site

City

Curitiba

State/Province

Paraná

ZIP/Postal Code

80730150

Country

Brazil

Facility Name

GSK Investigational Site

City

Pelotas

State/Province

Rio Grande Do Sul

ZIP/Postal Code

96015-290

Country

Brazil

Facility Name

GSK Investigational Site

City

Porto Alegre

State/Province

Rio Grande Do Sul

ZIP/Postal Code

90610000

Country

Brazil

Facility Name

GSK Investigational Site

City

Porto Alegre

State/Province

Rio Grande Do Sul

ZIP/Postal Code

90880-480

Country

Brazil

Facility Name

GSK Investigational Site

City

Natal

State/Province

Rio Grande Du Norte

ZIP/Postal Code

59020-100

Country

Brazil

Facility Name

GSK Investigational Site

City

Campinas

State/Province

São Paulo

ZIP/Postal Code

13059740

Country

Brazil

Facility Name

GSK Investigational Site

City

São José do Rio Preto

State/Province

São Paulo

ZIP/Postal Code

15015210

Country

Brazil

Facility Name

GSK Investigational Site

City

São José do Rio Preto

State/Province

São Paulo

ZIP/Postal Code

15090-000

Country

Brazil

Facility Name

GSK Investigational Site

City

Rio de Janeiro

ZIP/Postal Code

20551-030

Country

Brazil

Facility Name

GSK Investigational Site

City

São Paulo

ZIP/Postal Code

04012-909

Country

Brazil

Facility Name

GSK Investigational Site

City

São Paulo

ZIP/Postal Code

04012180

Country

Brazil

Facility Name

GSK Investigational Site

City

São Paulo

ZIP/Postal Code

05403-000

Country

Brazil

Facility Name

GSK Investigational Site

City

São Paulo

ZIP/Postal Code

05403000

Country

Brazil

Facility Name

GSK Investigational Site

City

Dimitrovgrad

ZIP/Postal Code

6400

Country

Bulgaria

Facility Name

GSK Investigational Site

City

Pleven

ZIP/Postal Code

5800

Country

Bulgaria

Facility Name

GSK Investigational Site

City

Plovdiv

ZIP/Postal Code

4003

Country

Bulgaria

Facility Name

GSK Investigational Site

City

Ruse

ZIP/Postal Code

7002

Country

Bulgaria

Facility Name

GSK Investigational Site

City

Sofia

ZIP/Postal Code

1000

Country

Bulgaria

Facility Name

GSK Investigational Site

City

Sofia

ZIP/Postal Code

1233

Country

Bulgaria

Facility Name

GSK Investigational Site

City

Sofia

ZIP/Postal Code

1431

Country

Bulgaria

Facility Name

GSK Investigational Site

City

Sofia

ZIP/Postal Code

1527

Country

Bulgaria

Facility Name

GSK Investigational Site

City

Sofia

ZIP/Postal Code

1606

Country

Bulgaria

Facility Name

GSK Investigational Site

City

Veliko Tarnovo

ZIP/Postal Code

5000

Country

Bulgaria

Facility Name

GSK Investigational Site

City

Edmonton

State/Province

Alberta

ZIP/Postal Code

T6G 2B7

Country

Canada

Facility Name

GSK Investigational Site

City

Kelowna

State/Province

British Columbia

ZIP/Postal Code

V1Y 1E4

Country

Canada

Facility Name

GSK Investigational Site

City

New Westminister

State/Province

British Columbia

ZIP/Postal Code

V3L 3W4

Country

Canada

Facility Name

GSK Investigational Site

City

New Westminster

State/Province

British Columbia

ZIP/Postal Code

V3L 3W4

Country

Canada

Facility Name

GSK Investigational Site

City

Surrey

State/Province

British Columbia

ZIP/Postal Code

V3V 1N1

Country

Canada

Facility Name

GSK Investigational Site

City

Vancouver

State/Province

British Columbia

ZIP/Postal Code

V5Z 1M9

Country

Canada

Facility Name

GSK Investigational Site

City

Victoria

State/Province

British Columbia

ZIP/Postal Code

V8R 4R2

Country

Canada

Facility Name

GSK Investigational Site

City

Winnipeg

State/Province

Manitoba

ZIP/Postal Code

R2H 2A6

Country

Canada

Facility Name

GSK Investigational Site

City

Bay Roberts

State/Province

Newfoundland and Labrador

ZIP/Postal Code

A0A 1G0

Country

Canada

Facility Name

GSK Investigational Site

City

St. John's

State/Province

Newfoundland and Labrador

ZIP/Postal Code

A1B 3V6

Country

Canada

Facility Name

GSK Investigational Site

City

Halifax

State/Province

Nova Scotia

ZIP/Postal Code

B3H 3A7

Country

Canada

Facility Name

GSK Investigational Site

City

Truro

State/Province

Nova Scotia

ZIP/Postal Code

B2N 1L2

Country

Canada

Facility Name

GSK Investigational Site

City

Ajax

State/Province

Ontario

ZIP/Postal Code

L1S 7K8

Country

Canada

Facility Name

GSK Investigational Site

City

Brampton

State/Province

Ontario

ZIP/Postal Code

L6Z 4N5

Country

Canada

Facility Name

GSK Investigational Site

City

Hamilton

State/Province

Ontario

ZIP/Postal Code

L8L 2X2

Country

Canada

Facility Name

GSK Investigational Site

City

Kitchener

State/Province

Ontario

ZIP/Postal Code

N2M 5N6

Country

Canada

Facility Name

GSK Investigational Site

City

Mississauga

State/Province

Ontario

ZIP/Postal Code

L5B 2P7

Country

Canada

Facility Name

GSK Investigational Site

City

Oshawa

State/Province

Ontario

ZIP/Postal Code

L1J 2J9

Country

Canada

Facility Name

GSK Investigational Site

City

Ottawa

State/Province

Ontario

ZIP/Postal Code

K1Y 4W7

Country

Canada

Facility Name

GSK Investigational Site

City

Scarborough

State/Province

Ontario

ZIP/Postal Code

M1E 5E9

Country

Canada

Facility Name

GSK Investigational Site

City

Thornhill

State/Province

Ontario

ZIP/Postal Code

L4J 8L7

Country

Canada

Facility Name

GSK Investigational Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M3H 5S4

Country

Canada

Facility Name

GSK Investigational Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M4G 3E8

Country

Canada

Facility Name

GSK Investigational Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M5C 2T2

Country

Canada

Facility Name

GSK Investigational Site

City

Gatineau

State/Province

Quebec

ZIP/Postal Code

J8Y 6S8

Country

Canada

Facility Name

GSK Investigational Site

City

Greenfield Park

State/Province

Quebec

ZIP/Postal Code

J4V 2H1

Country

Canada

Facility Name

GSK Investigational Site

City

Levis

State/Province

Quebec

ZIP/Postal Code

G6V 4Z5

Country

Canada

Facility Name

GSK Investigational Site

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H1T 1C8

Country

Canada

Facility Name

GSK Investigational Site

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H1T 3Y7

Country

Canada

Facility Name

GSK Investigational Site

City

Quebec City

State/Province

Quebec

ZIP/Postal Code

G1J 1Z6

Country

Canada

Facility Name

GSK Investigational Site

City

Quebec City

State/Province

Quebec

ZIP/Postal Code

G1L 3L5

Country

Canada

Facility Name

GSK Investigational Site

City

Saint Charles-Borromee

State/Province

Quebec

ZIP/Postal Code

J6E 6J2

Country

Canada

Facility Name

GSK Investigational Site

City

Sherbrooke

State/Province

Quebec

ZIP/Postal Code

J1J 2E3

Country

Canada

Facility Name

GSK Investigational Site

City

Trois Rivières

State/Province

Quebec

ZIP/Postal Code

G8T 7A1

Country

Canada

Facility Name

GSK Investigational Site

City

Talcahuano

State/Province

Región Del Biobio

ZIP/Postal Code

427 0918

Country

Chile

Facility Name

GSK Investigational Site

City

Santiago

State/Province

Región Metro De Santiago

ZIP/Postal Code

750 0922

Country

Chile

Facility Name

GSK Investigational Site

City

Santiago

State/Province

Región Metro De Santiago

ZIP/Postal Code

7500503

Country

Chile

Facility Name

GSK Investigational Site

City

Santiago

State/Province

Región Metro De Santiago

ZIP/Postal Code

7571831

Country

Chile

Facility Name

GSK Investigational Site

City

Santiago

State/Province

Región Metro De Santiago

ZIP/Postal Code

833 0074

Country

Chile

Facility Name

GSK Investigational Site

City

Santiago

State/Province

Región Metro De Santiago

ZIP/Postal Code

8360160

Country

Chile

Facility Name

GSK Investigational Site

City

Santiago

State/Province

Región Metro De Santiago

ZIP/Postal Code

8380456

Country

Chile

Facility Name

GSK Investigational Site

City

Viña del Mar

State/Province

Valparaíso

Country

Chile

Facility Name

GSK Investigational Site

City

Guangzhou

State/Province

Guangdong

ZIP/Postal Code

510080

Country

China

Facility Name

GSK Investigational Site

City

Nanjing

State/Province

Jiangsu

ZIP/Postal Code

210029

Country

China

Facility Name

GSK Investigational Site

City

Xian

State/Province

Shaanxi

ZIP/Postal Code

710061

Country

China

Facility Name

GSK Investigational Site

City

Jinan

State/Province

Shandong

ZIP/Postal Code

250012

Country

China

Facility Name

GSK Investigational Site

City

Hang Zhou

State/Province

Zhejiang

ZIP/Postal Code

310003

Country

China

Facility Name

GSK Investigational Site

City

Beijing

ZIP/Postal Code

100034

Country

China

Facility Name

GSK Investigational Site

City

Beijing

ZIP/Postal Code

100044

Country

China

Facility Name

GSK Investigational Site

City

Beijing

ZIP/Postal Code

100730

Country

China

Facility Name

GSK Investigational Site

City

Beijing

ZIP/Postal Code

100853

Country

China

Facility Name

GSK Investigational Site

City

Guangzhou

ZIP/Postal Code

510100

Country

China

Facility Name

GSK Investigational Site

City

Haerbin

ZIP/Postal Code

150001

Country

China

Facility Name

GSK Investigational Site

City

Shanghai

ZIP/Postal Code

200032

Country

China

Facility Name

GSK Investigational Site

City

Shanghai

ZIP/Postal Code

200040

Country

China

Facility Name

GSK Investigational Site

City

Shanghai

ZIP/Postal Code

200127

Country

China

Facility Name

GSK Investigational Site

City

Shanghai

ZIP/Postal Code

200233

Country

China

Facility Name

GSK Investigational Site

City

Wuhan

ZIP/Postal Code

430022

Country

China

Facility Name

GSK Investigational Site

City

Caslav

ZIP/Postal Code

286 01

Country

Czechia

Facility Name

GSK Investigational Site

City

Chomutov

ZIP/Postal Code

430 02

Country

Czechia

Facility Name

GSK Investigational Site

City

Chrudim

ZIP/Postal Code

537 27

Country

Czechia

Facility Name

GSK Investigational Site

City

Jihlava

ZIP/Postal Code

586 33

Country

Czechia

Facility Name

GSK Investigational Site

City

Kladno

ZIP/Postal Code

272 80

Country

Czechia

Facility Name

GSK Investigational Site

City

Kolin

ZIP/Postal Code

280 00

Country

Czechia

Facility Name

GSK Investigational Site

City

Kromeriz

ZIP/Postal Code

767 55

Country

Czechia

Facility Name

GSK Investigational Site

City

Milevsko

ZIP/Postal Code

399 01

Country

Czechia

Facility Name

GSK Investigational Site

City

Pisek

ZIP/Postal Code

397 01

Country

Czechia

Facility Name

GSK Investigational Site

City

Praha 2

ZIP/Postal Code

128 08

Country

Czechia

Facility Name

GSK Investigational Site

City

Pribram

ZIP/Postal Code

261 26

Country

Czechia

Facility Name

GSK Investigational Site

City

Slany

Country

Czechia

Facility Name

GSK Investigational Site

City

Svitavy

ZIP/Postal Code

568 25

Country

Czechia

Facility Name

GSK Investigational Site

City

Tabor

ZIP/Postal Code

390 03

Country

Czechia

Facility Name

GSK Investigational Site

City

Usti nad Orlici

ZIP/Postal Code

562 18

Country

Czechia

Facility Name

GSK Investigational Site

City

Aarhus

ZIP/Postal Code

DK-8000

Country

Denmark

Facility Name

GSK Investigational Site

City

Esbjerg

ZIP/Postal Code

6700

Country

Denmark

Facility Name

GSK Investigational Site

City

Koebenhavn OE

ZIP/Postal Code

2100

Country

Denmark

Facility Name

GSK Investigational Site

City

Silkeborg

ZIP/Postal Code

8600

Country

Denmark

Facility Name

GSK Investigational Site

City

Tallinn

ZIP/Postal Code

1162

Country

Estonia

Facility Name

GSK Investigational Site

City

Tallinn

ZIP/Postal Code

13419

Country

Estonia

Facility Name

GSK Investigational Site

City

Tartu

ZIP/Postal Code

51014

Country

Estonia

Facility Name

GSK Investigational Site

City

Aix en Provence cedex 1

ZIP/Postal Code

13616

Country

France

Facility Name

GSK Investigational Site

City

Avignon

ZIP/Postal Code

84082

Country

France

Facility Name

GSK Investigational Site

City

Besançon Cedex

ZIP/Postal Code

25030

Country

France

Facility Name

GSK Investigational Site

City

Bron Cedex

ZIP/Postal Code

69677

Country

France

Facility Name

GSK Investigational Site

City

Créteil

ZIP/Postal Code

94010

Country

France

Facility Name

GSK Investigational Site

City

Dijon

ZIP/Postal Code

21079

Country

France

Facility Name

GSK Investigational Site

City

Lille Cedex

ZIP/Postal Code

59037

Country

France

Facility Name

GSK Investigational Site

City

Marseille cedex 5

ZIP/Postal Code

13385

Country

France

Facility Name

GSK Investigational Site

City

Metz Cedex 03

ZIP/Postal Code

57085

Country

France

Facility Name

GSK Investigational Site

City

Nantes Cedex 1

ZIP/Postal Code

44093

Country

France

Facility Name

GSK Investigational Site

City

Narbonne Cedex

ZIP/Postal Code

11108

Country

France

Facility Name

GSK Investigational Site

City

Nimes

ZIP/Postal Code

30000

Country

France

Facility Name

GSK Investigational Site

City

Paris Cedex 13

ZIP/Postal Code

75651

Country

France

Facility Name

GSK Investigational Site

City

Paris Cedex 18

ZIP/Postal Code

75877

Country

France

Facility Name

GSK Investigational Site

City

Paris

ZIP/Postal Code

75010

Country

France

Facility Name

GSK Investigational Site

City

Paris

ZIP/Postal Code

75015

Country

France

Facility Name

GSK Investigational Site

City

Pessac cedex

ZIP/Postal Code

33604

Country

France

Facility Name

GSK Investigational Site

City

Roubaix

ZIP/Postal Code

59056

Country

France

Facility Name

GSK Investigational Site

City

Strasbourg cedex

ZIP/Postal Code

67091

Country

France

Facility Name

GSK Investigational Site

City

Toulouse Cedex 09

ZIP/Postal Code

31059

Country

France

Facility Name

GSK Investigational Site

City

Tourcoing

ZIP/Postal Code

59208

Country

France

Facility Name

GSK Investigational Site

City

Deggingen

State/Province

Baden-Wuerttemberg

ZIP/Postal Code

73326

Country

Germany

Facility Name

GSK Investigational Site

City

Gueglingen

State/Province

Baden-Wuerttemberg

ZIP/Postal Code

74363

Country

Germany

Facility Name

GSK Investigational Site

City

Heidelberg

State/Province

Baden-Wuerttemberg

ZIP/Postal Code

69120

Country

Germany

Facility Name

GSK Investigational Site

City

Ulm

State/Province

Baden-Wuerttemberg

ZIP/Postal Code

89081

Country

Germany

Facility Name

GSK Investigational Site

City

Aschaffenburg

State/Province

Bayern

ZIP/Postal Code

63739

Country

Germany

Facility Name

GSK Investigational Site

City

Haag

State/Province

Bayern

ZIP/Postal Code

83527

Country

Germany

Facility Name

GSK Investigational Site

City

Hoehenkirchen-Siegertsbrunn

State/Province

Bayern

ZIP/Postal Code

85635

Country

Germany

Facility Name

GSK Investigational Site

City

Kuenzing

State/Province

Bayern

ZIP/Postal Code

94550

Country

Germany

Facility Name

GSK Investigational Site

City

Muehldorf

State/Province

Bayern

ZIP/Postal Code

84453

Country

Germany

Facility Name

GSK Investigational Site

City

Muenchen

State/Province

Bayern

ZIP/Postal Code

80336

Country

Germany

Facility Name

GSK Investigational Site

City

Sulzbach-Rosenberg

State/Province

Bayern

ZIP/Postal Code

92237

Country

Germany

Facility Name

GSK Investigational Site

City

Wallerfing

State/Province

Bayern

ZIP/Postal Code

94574

Country

Germany

Facility Name

GSK Investigational Site

City

Bernau

State/Province

Brandenburg

ZIP/Postal Code

16321

Country

Germany

Facility Name

GSK Investigational Site

City

Frankfurt/M.

State/Province

Hessen

ZIP/Postal Code

60594

Country

Germany

Facility Name

GSK Investigational Site

City

Kelkheim

State/Province

Hessen

ZIP/Postal Code

65779

Country

Germany

Facility Name

GSK Investigational Site

City

Hannover

State/Province

Niedersachsen

ZIP/Postal Code

30625

Country

Germany

Facility Name

GSK Investigational Site

City

Weyhe-Leeste

State/Province

Niedersachsen

ZIP/Postal Code

28844

Country

Germany

Facility Name

GSK Investigational Site

City

Bad Oeynhausen

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

32545

Country

Germany

Facility Name

GSK Investigational Site

City

Dorsten

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

46282

Country

Germany

Facility Name

GSK Investigational Site

City

Eschweiler

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

52249

Country

Germany

Facility Name

GSK Investigational Site

City

Essen

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

45359

Country

Germany

Facility Name

GSK Investigational Site

City

Goch

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

47574

Country

Germany

Facility Name

GSK Investigational Site

City

Herford

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

32049

Country

Germany

Facility Name

GSK Investigational Site

City

Lienen-Kattenvenne

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

49536

Country

Germany

Facility Name

GSK Investigational Site

City

Witten

State/Province

Nordrhein-Westfalen

ZIP/Postal Code

58455

Country

Germany

Facility Name

GSK Investigational Site

City

Mainz

State/Province

Rheinland-Pfalz

ZIP/Postal Code

55116

Country

Germany

Facility Name

GSK Investigational Site

City

Rhaunen

State/Province

Rheinland-Pfalz

ZIP/Postal Code

55624

Country

Germany

Facility Name

GSK Investigational Site

City

Magdeburg

State/Province

Sachsen-Anhalt

ZIP/Postal Code

39112

Country

Germany

Facility Name

GSK Investigational Site

City

Delitzsch

State/Province

Sachsen

ZIP/Postal Code

04509

Country

Germany

Facility Name

GSK Investigational Site

City

Dresden

State/Province

Sachsen

ZIP/Postal Code

01307

Country

Germany

Facility Name

GSK Investigational Site

City

Leipzg

State/Province

Sachsen

ZIP/Postal Code

04109

Country

Germany

Facility Name

GSK Investigational Site

City

Leipzig

State/Province

Sachsen

ZIP/Postal Code

04315

Country

Germany

Facility Name

GSK Investigational Site

City

Leipzig

State/Province

Sachsen

ZIP/Postal Code

04329

Country

Germany

Facility Name

GSK Investigational Site

City

Schmiedeberg

State/Province

Sachsen

ZIP/Postal Code

01762

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

10367

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

10559

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

10787

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

12157

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

13055

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

13086

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

13125

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

13347

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

13353

Country

Germany

Facility Name

GSK Investigational Site

City

Berlin

ZIP/Postal Code

13405

Country

Germany

Facility Name

GSK Investigational Site

City

Hamburg

ZIP/Postal Code

22041

Country

Germany

Facility Name

GSK Investigational Site

City

Agia Varvara, Athens

ZIP/Postal Code

123 51

Country

Greece

Facility Name

GSK Investigational Site

City

Alexandroupolis

ZIP/Postal Code

68100

Country

Greece

Facility Name

GSK Investigational Site

City

Athens

ZIP/Postal Code

11527

Country

Greece

Facility Name

GSK Investigational Site

City

Athens

ZIP/Postal Code

124 62

Country

Greece

Facility Name

GSK Investigational Site

City

Athens

ZIP/Postal Code

176 74

Country

Greece

Facility Name

GSK Investigational Site

City

Chalkida

ZIP/Postal Code

341 00

Country

Greece

Facility Name

GSK Investigational Site

City

Ioannina

ZIP/Postal Code

45500

Country

Greece

Facility Name

GSK Investigational Site

City

Magoula, Elefsina

ZIP/Postal Code

192 00

Country

Greece

Facility Name

GSK Investigational Site

City

Patras

ZIP/Postal Code

26 500

Country

Greece

Facility Name

GSK Investigational Site

City

Thessaloniki

ZIP/Postal Code

546 42

Country

Greece

Facility Name

GSK Investigational Site

City

Voula / Athens

ZIP/Postal Code

166 73

Country

Greece

Facility Name

GSK Investigational Site

City

Hong Kong

Country

Hong Kong

Facility Name

GSK Investigational Site

City

Shatin, New Territories

Country

Hong Kong

Facility Name

GSK Investigational Site

City

Berettyóújfalu

Country

Hungary

Facility Name

GSK Investigational Site

City

Budapest

ZIP/Postal Code

1032

Country

Hungary

Facility Name

GSK Investigational Site

City

Budapest

ZIP/Postal Code

1033

Country

Hungary

Facility Name

GSK Investigational Site

City

Budapest

ZIP/Postal Code

1096

Country

Hungary

Facility Name

GSK Investigational Site

City

Esztergom

Country

Hungary

Facility Name

GSK Investigational Site

City

Gyula

ZIP/Postal Code

5700

Country

Hungary

Facility Name

GSK Investigational Site

City

Komárom

ZIP/Postal Code

2921

Country

Hungary

Facility Name

GSK Investigational Site

City

Mosonmagyaróvár

ZIP/Postal Code

9200

Country

Hungary

Facility Name

GSK Investigational Site

City

Szikszó

Country

Hungary

Facility Name

GSK Investigational Site

City

Szolnok

ZIP/Postal Code

5004

Country

Hungary

Facility Name

GSK Investigational Site

City

Székesfehérvár

ZIP/Postal Code

8000

Country

Hungary

Facility Name

GSK Investigational Site

City

Sátoraljaújhely

ZIP/Postal Code

3980

Country

Hungary

Facility Name

GSK Investigational Site

City

Ahmedabad

ZIP/Postal Code

380060

Country

India

Facility Name

GSK Investigational Site

City

Bangalore

ZIP/Postal Code

560 099

Country

India

Facility Name

GSK Investigational Site

City

Bangalore

ZIP/Postal Code

560034

Country

India

Facility Name

GSK Investigational Site

City

Cochin

ZIP/Postal Code

683572

Country

India

Facility Name

GSK Investigational Site

City

Jaipur

ZIP/Postal Code

302001

Country

India

Facility Name

GSK Investigational Site

City

Jaipur

ZIP/Postal Code

302017

Country

India

Facility Name

GSK Investigational Site

City

Mysore

ZIP/Postal Code

570020

Country

India

Facility Name

GSK Investigational Site

City

New Delhi

ZIP/Postal Code

110060

Country

India

Facility Name

GSK Investigational Site

City

Patiala

ZIP/Postal Code

147001

Country

India

Facility Name

GSK Investigational Site

City

Pune

ZIP/Postal Code

411004

Country

India

Facility Name

GSK Investigational Site

City

Pune

ZIP/Postal Code

411030

Country

India

Facility Name

GSK Investigational Site

City

Saket,Delhi

ZIP/Postal Code

110017

Country

India

Facility Name

GSK Investigational Site

City

Vadodara

ZIP/Postal Code

390015

Country

India

Facility Name

GSK Investigational Site

City

Vijayawada

ZIP/Postal Code

520008

Country

India

Facility Name

GSK Investigational Site

City

Chieti

State/Province

Abruzzo

ZIP/Postal Code

66013

Country

Italy

Facility Name

GSK Investigational Site

City

Napoli

State/Province

Campania

ZIP/Postal Code

80131

Country

Italy

Facility Name

GSK Investigational Site

City

Carpi

State/Province

Emilia-Romagna

ZIP/Postal Code

41012

Country

Italy

Facility Name

GSK Investigational Site

City

Cona (Ferrara)

State/Province

Emilia-Romagna

ZIP/Postal Code

44124

Country

Italy

Facility Name

GSK Investigational Site

City

Parma

State/Province

Emilia-Romagna

ZIP/Postal Code

43100

Country

Italy

Facility Name

GSK Investigational Site

City

Roma

State/Province

Lazio

ZIP/Postal Code

00135

Country

Italy

Facility Name

GSK Investigational Site

City

Milano

State/Province

Lombardia

ZIP/Postal Code

20162

Country

Italy

Facility Name

GSK Investigational Site

City

Ascoli Piceno

State/Province

Marche

ZIP/Postal Code

63100

Country

Italy

Facility Name

GSK Investigational Site

City

Cuneo

State/Province

Piemonte

ZIP/Postal Code

12100

Country

Italy

Facility Name

GSK Investigational Site

City

Novara

State/Province

Piemonte

ZIP/Postal Code

28100

Country

Italy

Facility Name

GSK Investigational Site

City

Pisa

State/Province

Toscana

ZIP/Postal Code

56126

Country

Italy

Facility Name

GSK Investigational Site

City

Treviso

State/Province

Veneto

ZIP/Postal Code

31100

Country

Italy

Facility Name

GSK Investigational Site

City

Aichi

ZIP/Postal Code

487-0013

Country

Japan

Facility Name

GSK Investigational Site

City

Chiba

ZIP/Postal Code

270-2251

Country

Japan

Facility Name

GSK Investigational Site

City

Fukuoka

ZIP/Postal Code

802-8555

Country

Japan

Facility Name

GSK Investigational Site

City

Fukuoka

ZIP/Postal Code

811-3195

Country

Japan

Facility Name

GSK Investigational Site

City

Fukuoka

ZIP/Postal Code

819-1104

Country

Japan

Facility Name

GSK Investigational Site

City

Hokkaido

ZIP/Postal Code

063-0005

Country

Japan

Facility Name

GSK Investigational Site

City

Hokkaido

ZIP/Postal Code

065-0033

Country

Japan

Facility Name

GSK Investigational Site

City

Kagoshima

ZIP/Postal Code

892-0853

Country

Japan

Facility Name

GSK Investigational Site

City

Kanagawa

ZIP/Postal Code

240-0116

Country

Japan

Facility Name

GSK Investigational Site

City

Kanagawa

ZIP/Postal Code

247-8533

Country

Japan

Facility Name

GSK Investigational Site

City

Kyoto

ZIP/Postal Code

611-0042

Country

Japan

Facility Name

GSK Investigational Site

City

Nagano

ZIP/Postal Code

386-8610

Country

Japan

Facility Name

GSK Investigational Site

City

Nagasaki

ZIP/Postal Code

856-8562

Country

Japan

Facility Name

GSK Investigational Site

City

Nagasaki

ZIP/Postal Code

859-3615

Country

Japan

Facility Name

GSK Investigational Site

City

Oita

ZIP/Postal Code

870-1133

Country

Japan

Facility Name

GSK Investigational Site

City

Osaka

ZIP/Postal Code

574-0074

Country

Japan

Facility Name

GSK Investigational Site

City

Shiga

ZIP/Postal Code

520-2192

Country

Japan

Facility Name

GSK Investigational Site

City

Shizuoka

ZIP/Postal Code

411-8611

Country

Japan

Facility Name

GSK Investigational Site

City

Tokyo

ZIP/Postal Code

141-0001

Country

Japan

Facility Name

GSK Investigational Site

City

Cheongju

ZIP/Postal Code

361-711

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Dae-Gu

ZIP/Postal Code

700-721

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Gangnam-gu, Seoul

ZIP/Postal Code

135-710

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Gwangju

ZIP/Postal Code

501-757

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

jeonju-si, Jeollabuk-Do

ZIP/Postal Code

561-712

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seo-gu Busan

ZIP/Postal Code

602-739

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seongnam-si Gyeonggi-do

ZIP/Postal Code

463-707

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

110-744

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

120-752

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

130-702

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

136-705

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

137-701

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

138-736

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Seoul

ZIP/Postal Code

143-729

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Uijeongbu-si Kyonggi-do

ZIP/Postal Code

480-717

Country

Korea, Republic of

Facility Name

GSK Investigational Site

City

Monterrey NL

State/Province

Nuevo León

ZIP/Postal Code

64718

Country

Mexico

Facility Name

GSK Investigational Site

City

Durango

ZIP/Postal Code

34080

Country

Mexico

Facility Name

GSK Investigational Site

City

Mexico

ZIP/Postal Code

10700

Country

Mexico

Facility Name

GSK Investigational Site

City

México D.F,

ZIP/Postal Code

07760

Country

Mexico

Facility Name

GSK Investigational Site

City

Amsterdam

ZIP/Postal Code

1105 AZ

Country

Netherlands

Facility Name

GSK Investigational Site

City

Beverwijk

ZIP/Postal Code

1942 LE

Country

Netherlands

Facility Name

GSK Investigational Site

City

Den Haag

ZIP/Postal Code

2597 AX

Country

Netherlands

Facility Name

GSK Investigational Site

City

Doetinchem

ZIP/Postal Code

7009 BL

Country

Netherlands

Facility Name

GSK Investigational Site

City

Eindhoven

ZIP/Postal Code

5623 EJ

Country

Netherlands

Facility Name

GSK Investigational Site

City

Enschede

ZIP/Postal Code

7513 ER

Country

Netherlands

Facility Name

GSK Investigational Site

City

Goes

ZIP/Postal Code

4462 RA

Country

Netherlands

Facility Name

GSK Investigational Site

City

Harderwijk

ZIP/Postal Code

3844 DG

Country

Netherlands

Facility Name

GSK Investigational Site

City

Hoofddorp

ZIP/Postal Code

2134 TM

Country

Netherlands

Facility Name

GSK Investigational Site

City

Leeuwarden

ZIP/Postal Code

8934 AD

Country

Netherlands

Facility Name

GSK Investigational Site

City

Rotterdam

ZIP/Postal Code

3079 DZ

Country

Netherlands

Facility Name

GSK Investigational Site

City

Sittard-geleen

ZIP/Postal Code

6162 BG

Country

Netherlands

Facility Name

GSK Investigational Site

City

Sneek

ZIP/Postal Code

8601 ZK

Country

Netherlands

Facility Name

GSK Investigational Site

City

Tiel

ZIP/Postal Code

4002 WP

Country

Netherlands

Facility Name

GSK Investigational Site

City

Christchurch

Country

New Zealand

Facility Name

GSK Investigational Site

City

Dunedin

Country

New Zealand

Facility Name

GSK Investigational Site

City

Grafton, Auckland

ZIP/Postal Code

1030

Country

New Zealand

Facility Name

GSK Investigational Site

City

Hamilton

ZIP/Postal Code

3204

Country

New Zealand

Facility Name

GSK Investigational Site

City

Lower Hutt

Country

New Zealand

Facility Name

GSK Investigational Site

City

Nelson

Country

New Zealand

Facility Name

GSK Investigational Site

City

Otahuhu, Auckland

ZIP/Postal Code

1640

Country

New Zealand

Facility Name

GSK Investigational Site

City

Palmerston North

ZIP/Postal Code

4410

Country

New Zealand

Facility Name

GSK Investigational Site

City

Takapuna, Auckland

ZIP/Postal Code

0622

Country

New Zealand

Facility Name

GSK Investigational Site

City

Tauranga

ZIP/Postal Code

3112

Country

New Zealand

Facility Name

GSK Investigational Site

City

Timaru

ZIP/Postal Code

7910

Country

New Zealand

Facility Name

GSK Investigational Site

City

Whangarei

Country

New Zealand

Facility Name

GSK Investigational Site

City

Bergen

ZIP/Postal Code

5021

Country

Norway

Facility Name

GSK Investigational Site

City

Moss

ZIP/Postal Code

1501

Country

Norway

Facility Name

GSK Investigational Site

City

Oslo

ZIP/Postal Code

0160

Country

Norway

Facility Name

GSK Investigational Site

City

Oslo

ZIP/Postal Code

0407

Country

Norway

Facility Name

GSK Investigational Site

City

Karachi

ZIP/Postal Code

75510

Country

Pakistan

Facility Name

GSK Investigational Site

City

Karachi

ZIP/Postal Code

75950

Country

Pakistan

Facility Name

GSK Investigational Site

City

Korangi / Karachi

Country

Pakistan

Facility Name

GSK Investigational Site

City

Lahore

ZIP/Postal Code

54000

Country

Pakistan

Facility Name

GSK Investigational Site

City

Lahore

Country

Pakistan

Facility Name

GSK Investigational Site

City

Multan

ZIP/Postal Code

60000

Country

Pakistan

Facility Name

GSK Investigational Site

City

Rawalpindi Cantt

ZIP/Postal Code

46000

Country

Pakistan

Facility Name

GSK Investigational Site

City

Jesus Maria

State/Province

Lima

ZIP/Postal Code

Lima 11

Country

Peru

Facility Name

GSK Investigational Site

City

Callao

ZIP/Postal Code

Callao 2

Country

Peru

Facility Name

GSK Investigational Site

City

Lima

ZIP/Postal Code

Lima 11

Country

Peru

Facility Name

GSK Investigational Site

City

Ermita, Manila

ZIP/Postal Code

1000

Country

Philippines

Facility Name

GSK Investigational Site

City

Manila

ZIP/Postal Code

1000

Country

Philippines

Facility Name

GSK Investigational Site

City

Manila

ZIP/Postal Code

1100

Country

Philippines

Facility Name

GSK Investigational Site

City

Quezon City

ZIP/Postal Code

1109

Country

Philippines

Facility Name

GSK Investigational Site

City

Quezon City

ZIP/Postal Code

1113

Country

Philippines

Facility Name

GSK Investigational Site

City

Quezon City

Country

Philippines

Facility Name

GSK Investigational Site

City

San Juan

ZIP/Postal Code

1502

Country

Philippines

Facility Name

GSK Investigational Site

City

Bydgoszcz

ZIP/Postal Code

85-079

Country

Poland

Facility Name

GSK Investigational Site

City

Bydgoszcz

ZIP/Postal Code

85-435

Country

Poland

Facility Name

GSK Investigational Site

City

Gdynia

ZIP/Postal Code

81-423

Country

Poland

Facility Name

GSK Investigational Site

City

Kowanowko

Country

Poland

Facility Name

GSK Investigational Site

City

Krakow

ZIP/Postal Code

31-202

Country

Poland

Facility Name

GSK Investigational Site

City

Mielec

ZIP/Postal Code

39-300

Country

Poland

Facility Name

GSK Investigational Site

City

Ostrow Wielkopolski

ZIP/Postal Code

63-400

Country

Poland

Facility Name

GSK Investigational Site

City

Plonsk

ZIP/Postal Code

09 - 100

Country

Poland

Facility Name

GSK Investigational Site

City

Radom

ZIP/Postal Code

26-617

Country

Poland

Facility Name

GSK Investigational Site

City

Ruda Slaska

ZIP/Postal Code

41-706

Country

Poland

Facility Name

GSK Investigational Site

City

Siemianowice Slaskie

ZIP/Postal Code

41-100

Country

Poland

Facility Name

GSK Investigational Site

City

Skierniewice

Country

Poland

Facility Name

GSK Investigational Site

City

Torun

ZIP/Postal Code

87-100

Country

Poland

Facility Name

GSK Investigational Site

City

Tychy

ZIP/Postal Code

43-100

Country

Poland

Facility Name

GSK Investigational Site

City

Warszawa

ZIP/Postal Code

03-285

Country

Poland

Facility Name

GSK Investigational Site

City

Warszawa

ZIP/Postal Code

04-073

Country

Poland

Facility Name

GSK Investigational Site

City

Wloclawek

ZIP/Postal Code

87-800

Country

Poland

Facility Name

GSK Investigational Site

City

Wroclaw

ZIP/Postal Code

50-349

Country

Poland

Facility Name

GSK Investigational Site

City

Bucharest

ZIP/Postal Code

011461

Country

Romania

Facility Name

GSK Investigational Site

City

Bucharest

ZIP/Postal Code

011601

Country

Romania

Facility Name

GSK Investigational Site

City

Bucharest

ZIP/Postal Code

011794

Country

Romania

Facility Name

GSK Investigational Site

City

Bucharest

ZIP/Postal Code

022328

Country

Romania

Facility Name

GSK Investigational Site

City

Bucharest

ZIP/Postal Code

041915

Country

Romania

Facility Name

GSK Investigational Site

City

Bucharest

ZIP/Postal Code

042122

Country

Romania

Facility Name

GSK Investigational Site

City

Bucharest

ZIP/Postal Code

050098

Country

Romania

Facility Name

GSK Investigational Site

City

Deva

ZIP/Postal Code

330084

Country

Romania

Facility Name

GSK Investigational Site

City

Galati

ZIP/Postal Code

800087

Country

Romania

Facility Name

GSK Investigational Site

City

Targu Mures

ZIP/Postal Code

540136

Country

Romania

Facility Name

GSK Investigational Site

City

Ekaterinburg

ZIP/Postal Code

620109

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Ekaterinburg

ZIP/Postal Code

620144

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Kemerovo

ZIP/Postal Code

650002

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Kemerovo

ZIP/Postal Code

650055

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Moscow

ZIP/Postal Code

111020

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Moscow

ZIP/Postal Code

111539

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Moscow

ZIP/Postal Code

117292

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Moscow

ZIP/Postal Code

119620

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Moscow

ZIP/Postal Code

121 552

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Moscow

ZIP/Postal Code

121552

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Novosibirsk

ZIP/Postal Code

630003

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Novosibirsk

ZIP/Postal Code

630008

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Novosibirsk

ZIP/Postal Code

630047

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Ryazan

ZIP/Postal Code

390026

Country

Russian Federation

Facility Name

GSK Investigational Site

City

S.-Petresburg

ZIP/Postal Code

195067

Country

Russian Federation

Facility Name

GSK Investigational Site

City

St Pertersburg

ZIP/Postal Code

196247

Country

Russian Federation

Facility Name

GSK Investigational Site

City

St'Petersburg

ZIP/Postal Code

194156

Country

Russian Federation

Facility Name

GSK Investigational Site

City

St-Petersburg

ZIP/Postal Code

193312

Country

Russian Federation

Facility Name

GSK Investigational Site

City

St-Petersburg

ZIP/Postal Code

195067

Country

Russian Federation

Facility Name

GSK Investigational Site

City

St-Petersburg

ZIP/Postal Code

199106

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Yekaterinburg

Country

Russian Federation

Facility Name

GSK Investigational Site

City

Bratislava

ZIP/Postal Code

813 69

Country

Slovakia

Facility Name

GSK Investigational Site

City

Bratislava

ZIP/Postal Code

833 05

Country

Slovakia

Facility Name

GSK Investigational Site

City

Kosice

ZIP/Postal Code

040 22

Country

Slovakia

Facility Name

GSK Investigational Site

City

Nitra

ZIP/Postal Code

949 01

Country

Slovakia

Facility Name

GSK Investigational Site

City

Parktown

State/Province

Gauteng

ZIP/Postal Code

2193

Country

South Africa

Facility Name

GSK Investigational Site

City

Bellville

ZIP/Postal Code

7531

Country

South Africa

Facility Name

GSK Investigational Site

City

Bloemfontein

ZIP/Postal Code

9301

Country

South Africa

Facility Name

GSK Investigational Site

City

Kempton Park

ZIP/Postal Code

1619

Country

South Africa

Facility Name

GSK Investigational Site

City

Kuils River

ZIP/Postal Code

7580

Country

South Africa

Facility Name

GSK Investigational Site

City

Moreletapark

ZIP/Postal Code

0181

Country

South Africa

Facility Name

GSK Investigational Site

City

Olivedale

ZIP/Postal Code

2188

Country

South Africa

Facility Name

GSK Investigational Site

City

Paarl

ZIP/Postal Code

7646

Country

South Africa

Facility Name

GSK Investigational Site

City

Parktown West

ZIP/Postal Code

2193

Country

South Africa

Facility Name

GSK Investigational Site

City

Parow

ZIP/Postal Code

7505

Country

South Africa

Facility Name

GSK Investigational Site

City

Pinelands

ZIP/Postal Code

7405

Country

South Africa

Facility Name

GSK Investigational Site

City

Somerset West

ZIP/Postal Code

7130

Country

South Africa

Facility Name

GSK Investigational Site

City

Soweto

ZIP/Postal Code

2013

Country

South Africa

Facility Name

GSK Investigational Site

City

Umhlanga

ZIP/Postal Code

4319

Country

South Africa

Facility Name

GSK Investigational Site

City

Alicante

ZIP/Postal Code

03114

Country

Spain

Facility Name

GSK Investigational Site

City

Granada

ZIP/Postal Code

18012

Country

Spain

Facility Name

GSK Investigational Site

City

Jerez de la Frontera

ZIP/Postal Code

11407

Country

Spain

Facility Name

GSK Investigational Site

City

Madrid

ZIP/Postal Code

28029

Country

Spain

Facility Name

GSK Investigational Site

City

Madrid

ZIP/Postal Code

28031

Country

Spain

Facility Name

GSK Investigational Site

City

Madrid

ZIP/Postal Code

28034

Country

Spain

Facility Name

GSK Investigational Site

City

Madrid

ZIP/Postal Code

28040

Country

Spain

Facility Name

GSK Investigational Site

City

Madrid

ZIP/Postal Code

28041

Country

Spain

Facility Name

GSK Investigational Site

City

Madrid

ZIP/Postal Code

28046

Country

Spain

Facility Name

GSK Investigational Site

City

Madrid

Country

Spain

Facility Name

GSK Investigational Site

City

Malaga

ZIP/Postal Code

29010

Country

Spain

Facility Name

GSK Investigational Site

City

Marid

ZIP/Postal Code

28040

Country

Spain

Facility Name

GSK Investigational Site

City

Oviedo

ZIP/Postal Code

33006

Country

Spain

Facility Name

GSK Investigational Site

City

Pozuelo de Alarcón/Madrid

ZIP/Postal Code

28223

Country

Spain

Facility Name

GSK Investigational Site

City

San Juan (Alicante)

ZIP/Postal Code

03550

Country

Spain

Facility Name

GSK Investigational Site

City

San Sebastián de los Reyes/Madrid

Country

Spain

Facility Name

GSK Investigational Site

City

San Sebastián

ZIP/Postal Code

20014

Country

Spain

Facility Name

GSK Investigational Site

City

Santander

ZIP/Postal Code

39008

Country

Spain

Facility Name

GSK Investigational Site

City

Sevilla

ZIP/Postal Code

41071

Country

Spain

Facility Name

GSK Investigational Site

City

Sta Coloma de Gramanet (Barcelona)

ZIP/Postal Code

08923

Country

Spain

Facility Name

GSK Investigational Site

City

Valdemoro/Madrid

ZIP/Postal Code

28340

Country

Spain

Facility Name

GSK Investigational Site

City

Eksjö

ZIP/Postal Code

SE-575 36

Country

Sweden

Facility Name

GSK Investigational Site

City

Göteborg

ZIP/Postal Code

SE-413 45

Country

Sweden

Facility Name

GSK Investigational Site

City

Göteborg

ZIP/Postal Code

SE-416 85

Country

Sweden

Facility Name

GSK Investigational Site

City

Linköping

ZIP/Postal Code

SE-581 85

Country

Sweden

Facility Name

GSK Investigational Site

City

Lund

ZIP/Postal Code

SE-222 21

Country

Sweden

Facility Name

GSK Investigational Site

City

Malmö

ZIP/Postal Code

SE-205 02

Country

Sweden

Facility Name

GSK Investigational Site

City

Stockholm

ZIP/Postal Code

SE-111 35

Country

Sweden

Facility Name

GSK Investigational Site

City

Stockholm

ZIP/Postal Code

SE-111 57

Country

Sweden

Facility Name

GSK Investigational Site

City

Stockholm

ZIP/Postal Code

SE-182 88

Country

Sweden

Facility Name

GSK Investigational Site

City

Umeå

ZIP/Postal Code

SE-901 85

Country

Sweden

Facility Name

GSK Investigational Site

City

Uppsala

ZIP/Postal Code

SE-751 85

Country

Sweden

Facility Name

GSK Investigational Site

City

Västervik

ZIP/Postal Code

SE-593 81

Country

Sweden

Facility Name

GSK Investigational Site

City

Västerås

ZIP/Postal Code

SE-721 89

Country

Sweden

Facility Name

GSK Investigational Site

City

Östersund

ZIP/Postal Code

SE-831 83

Country

Sweden

Facility Name

GSK Investigational Site

City

Changhua

ZIP/Postal Code

500

Country

Taiwan

Facility Name

GSK Investigational Site

City

Taichung

ZIP/Postal Code

407

Country

Taiwan

Facility Name

GSK Investigational Site

City

Tainan

ZIP/Postal Code

704

Country

Taiwan

Facility Name

GSK Investigational Site

City

Taipei City

ZIP/Postal Code

104

Country

Taiwan

Facility Name

GSK Investigational Site

City

Taipei

ZIP/Postal Code

100

Country

Taiwan

Facility Name

GSK Investigational Site

City

Taipei

ZIP/Postal Code

112

Country

Taiwan

Facility Name

GSK Investigational Site

City

Bangkok

ZIP/Postal Code

10330

Country

Thailand

Facility Name

GSK Investigational Site

City

Bangkok

ZIP/Postal Code

10400

Country

Thailand

Facility Name

GSK Investigational Site

City

Bangkok

ZIP/Postal Code

10700

Country

Thailand

Facility Name

GSK Investigational Site

City

Chiangmai

ZIP/Postal Code

50200

Country

Thailand

Facility Name

GSK Investigational Site

City

Donetsk

ZIP/Postal Code

83045

Country

Ukraine

Facility Name

GSK Investigational Site

City

Kharkiv

ZIP/Postal Code

61002

Country

Ukraine

Facility Name

GSK Investigational Site

City

Kharkiv

ZIP/Postal Code

61018

Country

Ukraine

Facility Name

GSK Investigational Site

City

Kharkiv

ZIP/Postal Code

61037

Country

Ukraine

Facility Name

GSK Investigational Site

City

Kharkiv

ZIP/Postal Code

61176

Country

Ukraine

Facility Name

GSK Investigational Site

City

Kyiv

ZIP/Postal Code

02660

Country

Ukraine

Facility Name

GSK Investigational Site

City

Kyiv

ZIP/Postal Code

03680

Country

Ukraine

Facility Name

GSK Investigational Site

City

Kyiv

ZIP/Postal Code

04114

Country

Ukraine

Facility Name

GSK Investigational Site

City

Lviv

ZIP/Postal Code

79044

Country

Ukraine

Facility Name

GSK Investigational Site

City

Odesa

ZIP/Postal Code

65025

Country

Ukraine

Facility Name

GSK Investigational Site

City

Odesa

ZIP/Postal Code

65114

Country

Ukraine

Facility Name

GSK Investigational Site

City

Vinnytsia

ZIP/Postal Code

21029

Country

Ukraine

Facility Name

GSK Investigational Site

City

Zaporizhzhia

ZIP/Postal Code

69118

Country

Ukraine

Facility Name

GSK Investigational Site

City

Cambridge

State/Province

Cambridgeshire

ZIP/Postal Code

CB2 0QQ

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Glasgow

State/Province

Lanarkshire

ZIP/Postal Code

G11 6NT

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Motherwell

State/Province

Lanarkshire

ZIP/Postal Code

ML1 3JX

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Chelsea

State/Province

London

ZIP/Postal Code

SW3 6NP

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Liverpool

State/Province

Merseyside

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Harrow

State/Province

Middlesex

ZIP/Postal Code

HA1 3UJ

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Chertsey

State/Province

Surrey

ZIP/Postal Code

KT16 0PZ

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Chichester

State/Province

Sussex West

ZIP/Postal Code

PO19 4SE

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Barnet

ZIP/Postal Code

EN5 3DJ

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Coatbridge

ZIP/Postal Code

ML5 3AP

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Cottingham

ZIP/Postal Code

HU16 5JQ

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Cumbernauld

ZIP/Postal Code

G67 1BJ

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Hamilton

ZIP/Postal Code

ML3 8AA

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Hertfordshire

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Liverpool

ZIP/Postal Code

L7 8XP

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Newcastle-upon-Tyne

ZIP/Postal Code

NE7 7DN

Country

United Kingdom

Facility Name

GSK Investigational Site

City

Paisley

ZIP/Postal Code

PA2 9PN

Country

United Kingdom

12. IPD Sharing Statement

Plan to Share IPD

Yes

IPD Sharing Plan Description

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Citations:

PubMed Identifier

35861814

Citation

Sjolin K, Aulin J, Wallentin L, Eriksson N, Held C, Kultima K, Oldgren J, Burman J. Serum Neurofilament Light Chain in Patients With Atrial Fibrillation. J Am Heart Assoc. 2022 Jul 19;11(14):e025910. doi: 10.1161/JAHA.122.025910. Epub 2022 Jul 15.

Results Reference

derived

PubMed Identifier

35060389

Citation

Held C, Hadziosmanovic N, Aylward PE, Hagstrom E, Hochman JS, Stewart RAH, White HD, Wallentin L. Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease - A STABILITY Substudy. J Am Heart Assoc. 2022 Feb;11(3):e023667. doi: 10.1161/JAHA.121.023667. Epub 2022 Jan 21.

Results Reference

derived

PubMed Identifier

34562103

Citation

Siddiqui MK, Smith G, St Jean P, Dawed AY, Bell S, Soto-Pedre E, Kennedy G, Carr F, Wallentin L, White H, Macphee CH, Waterworth D, Palmer CNA. Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events. Diabetologia. 2022 Jan;65(1):101-112. doi: 10.1007/s00125-021-05574-5. Epub 2021 Sep 25.

Results Reference

derived

PubMed Identifier

33439866

Citation

Wallentin L, Eriksson N, Olszowka M, Grammer TB, Hagstrom E, Held C, Kleber ME, Koenig W, Marz W, Stewart RAH, White HD, Aberg M, Siegbahn A. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. PLoS Med. 2021 Jan 13;18(1):e1003513. doi: 10.1371/journal.pmed.1003513. eCollection 2021 Jan.

Results Reference

derived

PubMed Identifier

32480059

Citation

White HD, Stewart RAH, Dalby AJ, Stebbins A, Cannon CP, Budaj A, Linhart A, Pais P, Diaz R, Steg PG, Krug-Gourley S, Granger CB, Hochman JS, Koenig W, Harrington RA, Held C, Wallentin L; STABILITY Investigators. In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. Am Heart J. 2020 Jul;225:97-107. doi: 10.1016/j.ahj.2020.04.004. Epub 2020 Apr 18.

Results Reference

derived

PubMed Identifier

32375553

Citation

Hilvo M, Wallentin L, Ghukasyan Lakic T, Held C, Kauhanen D, Jylha A, Lindback J, Siegbahn A, Granger CB, Koenig W, Stewart RAH, White H, Laaksonen R; STABILITY Investigators. Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy. J Am Heart Assoc. 2020 May 18;9(10):e015258. doi: 10.1161/JAHA.119.015258. Epub 2020 May 7.

Results Reference

derived

PubMed Identifier

30897999

Citation

Stewart RAH, Held C, Krug-Gourley S, Waterworth D, Stebbins A, Chiswell K, Hagstrom E, Armstrong PW, Wallentin L, White H. Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2019 Apr 2;8(7):e010641. doi: 10.1161/JAHA.118.010641.

Results Reference

derived

PubMed Identifier

29066452

Citation

Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Ostlund O, Wallentin L; STABILITY Investigators. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017 Oct 24;6(10):e005077. doi: 10.1161/JAHA.116.005077.

Results Reference

derived

PubMed Identifier

28960596

Citation

Hagstrom E, Norlund F, Stebbins A, Armstrong PW, Chiswell K, Granger CB, Lopez-Sendon J, Pella D, Soffer J, Sy R, Wallentin L, White HD, Stewart RAH, Held C. Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. J Intern Med. 2018 Jan;283(1):83-92. doi: 10.1111/joim.12692. Epub 2017 Oct 23.

Results Reference

derived

PubMed Identifier

28912210

Citation

Guimaraes PO, Granger CB, Stebbins A, Chiswell K, Held C, Hochman JS, Krug-Gourley S, Lonn E, Lopes RD, Stewart RAH, Vinereanu D, Wallentin L, White HD, Hagstrom E, Danchin N. Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017 Sep 14;6(9):e006695. doi: 10.1161/JAHA.117.006695.

Results Reference

derived

PubMed Identifier

28862971

Citation

Stewart RAH, Hagstrom E, Held C, Wang TKM, Armstrong PW, Aylward PE, Cannon CP, Koenig W, Lopez-Sendon JL, Mohler ER 3rd, Hadziosmanovic N, Krug-Gourley S, Ramos Corrales MA, Siddique S, Steg PG, White HD, Wallentin L; STABILITY Investigators. Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2017 Aug 22;6(8):e006096. doi: 10.1161/JAHA.117.006096.

Results Reference

derived

PubMed Identifier

28797349

Citation

Lindholm D, Lindback J, Armstrong PW, Budaj A, Cannon CP, Granger CB, Hagstrom E, Held C, Koenig W, Ostlund O, Stewart RAH, Soffer J, White HD, de Winter RJ, Steg PG, Siegbahn A, Kleber ME, Dressel A, Grammer TB, Marz W, Wallentin L. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. J Am Coll Cardiol. 2017 Aug 15;70(7):813-826. doi: 10.1016/j.jacc.2017.06.030.

Results Reference

derived

PubMed Identifier

28735759

Citation

Vedin O, Hagstrom E, Ostlund O, Avezum A, Budaj A, Flather MD, Harrington RA, Koenig W, Soffer J, Siegbahn A, Steg PG, Stewart RAH, Wallentin L, White HD, Held C; STABILITY Investigators. Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. Int J Cardiol. 2017 Oct 15;245:271-276. doi: 10.1016/j.ijcard.2017.07.036. Epub 2017 Jul 17.

Results Reference

derived

PubMed Identifier

27811204

Citation

Hagstrom E, Held C, Stewart RA, Aylward PE, Budaj A, Cannon CP, Koenig W, Krug-Gourley S, Mohler ER 3rd, Steg PG, Tarka E, Ostlund O, White HD, Siegbahn A, Wallentin L; STABILITY Investigators. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clin Chem. 2017 Jan;63(1):325-333. doi: 10.1373/clinchem.2016.260570. Epub 2016 Nov 3.

Results Reference

derived

PubMed Identifier

27329448

Citation

Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, Hagstrom E, Harrington RA, Hochman JS, Koenig W, Krug-Gourley S, Mohler ER 3rd, Siegbahn A, Tarka E, Steg PG, Stewart RA, Weiss R, Ostlund O, White HD; STABILITY Investigators. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2016 Jun 21;5(6):e003407. doi: 10.1161/JAHA.116.003407.

Results Reference

derived

PubMed Identifier

26920728

Citation

Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016 May 21;37(20):1582-90. doi: 10.1093/eurheartj/ehw054. Epub 2016 Feb 25.

Results Reference

derived

PubMed Identifier

26672609

Citation

Vedin O, Hagstrom E, Budaj A, Denchev S, Harrington RA, Koenig W, Soffer J, Sritara P, Stebbins A, Stewart RH, Swart HP, Viigimaa M, Vinereanu D, Wallentin L, White HD, Held C; STABILITY Investigators. Tooth loss is independently associated with poor outcomes in stable coronary heart disease. Eur J Prev Cardiol. 2016 May;23(8):839-46. doi: 10.1177/2047487315621978. Epub 2015 Dec 16.

Results Reference

derived

PubMed Identifier

24721691

Citation

Vedin O, Hagstrom E, Gallup D, Neely ML, Stewart R, Koenig W, Budaj A, Sritara P, Wallentin L, White HD, Held C. Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors. Eur J Prev Cardiol. 2015 Jun;22(6):771-8. doi: 10.1177/2047487314530660. Epub 2014 Apr 10.

Results Reference

derived

PubMed Identifier

24678955

Citation

STABILITY Investigators; White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, Lopez-Sendon J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014 May 1;370(18):1702-11. doi: 10.1056/NEJMoa1315878. Epub 2014 Mar 30.

Results Reference

derived

PubMed Identifier

22496275

Citation

Vedin O, Hagstrom E, Stewart R, Brown R, Krug-Gourley S, Davies R, Wallentin L, White H, Held C. Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. Eur J Prev Cardiol. 2013 Aug;20(4):678-85. doi: 10.1177/2047487312444995. Epub 2012 Apr 10.

Results Reference

derived

Links:

URL

https://www.clinicalstudydatarequest.com

Description

Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Available IPD and Supporting Information:

Available IPD/Information Type

Informed Consent Form

Available IPD/Information URL

https://www.clinicalstudydatarequest.com

Available IPD/Information Identifier

100601

Available IPD/Information Comments

For additional information about this study please refer to the GSK Clinical Study Register

Available IPD/Information Type

Clinical Study Report

Available IPD/Information URL

https://www.clinicalstudydatarequest.com

Available IPD/Information Identifier

100601

Available IPD/Information Comments

For additional information about this study please refer to the GSK Clinical Study Register

Available IPD/Information Type

Annotated Case Report Form

Available IPD/Information URL

https://www.clinicalstudydatarequest.com

Available IPD/Information Identifier

100601

Available IPD/Information Comments

For additional information about this study please refer to the GSK Clinical Study Register

Available IPD/Information Type

Study Protocol

Available IPD/Information URL

https://www.clinicalstudydatarequest.com

Available IPD/Information Identifier

100601

Available IPD/Information Comments

For additional information about this study please refer to the GSK Clinical Study Register

Available IPD/Information Type

Individual Participant Data Set

Available IPD/Information URL

https://www.clinicalstudydatarequest.com

Available IPD/Information Identifier

100601

Available IPD/Information Comments

For additional information about this study please refer to the GSK Clinical Study Register

Available IPD/Information Type

Statistical Analysis Plan

Available IPD/Information URL

https://www.clinicalstudydatarequest.com

Available IPD/Information Identifier

100601

Available IPD/Information Comments

For additional information about this study please refer to the GSK Clinical Study Register

Available IPD/Information Type

Dataset Specification

Available IPD/Information URL

https://www.clinicalstudydatarequest.com

Available IPD/Information Identifier

100601

Available IPD/Information Comments

For additional information about this study please refer to the GSK Clinical Study Register

Learn more about this trial

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

We'll reach out to this number within 24 hrs